In this post hoc study, we aimed to investigate liraglutide treatment on repetitive 24-hour blood pressure (BP) in patients with type II diabetes. Sixty-two individuals with type II diabetes (45 males) were randomized to 1.8 mg liraglutide once daily or 4 mg glimepiride together with 1 g metformin twice daily. Ambulatory 24-hour systolic and diastolic blood pressure (sBP/dBP) was repetitively measured at baseline, 2 weeks, and 18 weeks. Outcomes were evaluated as treatment change from baseline, 2 weeks, and 18 weeks. Baseline clinical characteristics of liraglutide (n = 33) and glimepiride (n = 29) groups were well matched. No statistically significant difference in 24-hour sBP/dBP between three time periods and groups was observed. There was no treatment change for 24-hour sBP at week 2 or after week 18. There was a transient treatment change in 24-hour dBP in the liraglutide group at week 2 (3.2 ± 5.4 vs. -1.2 ± 4.5 mm Hg, P < .01). A treatment change in 24-hour heart rate at week 2 (4.9 ± 6.8 vs. 1.0 ± 6.0 bpm, P = .03) and at week 18 (5.9 ± 7.8 vs. 0.2 ± 6.3 bpm, P < .01) was observed in the liraglutide group. In conclusion, liraglutide treatment did not lower BP. However, a small diurnal variation in dBP without affecting BP variability or nocturnal BP dipping was observed.

中文翻译：

---

随机接受利拉鲁肽或格列美脲治疗与二甲双胍联合治疗对II型糖尿病患者24小时动态血压的影响：一项随机分组的平行分组研究。

在这项事后研究中，我们旨在研究利拉鲁肽对II型糖尿病患者重复性24小时血压（BP）的治疗。62名II型糖尿病患者（45名男性）被随机分配至每天一次1.8 mg利拉鲁肽或每日两次两次与4 mg格列美脲和1 g二甲双胍随机分配。在基线，第2周和第18周重复测量24小时动态收缩压和舒张压（sBP / dBP）。评估结果为基线，2周和18周治疗改变。利拉鲁肽（n = 33）和格列美脲（n = 29）组的基线临床特征非常吻合。在三个时间段和三个组之间，在24小时sBP / dBP中没有观察到统计学上的显着差异。第2周或第18周后24小时sBP的治疗无变化。利拉鲁肽组在第2周的24小时dBP发生了短暂的治疗变化（3.2±5.4对-1.2±4.5 mm Hg，P <.01）。观察到第2周（4.9±6.8 vs. 1.0±6.0 bpm，P = .03）和第18周（5.9±7.8 vs. 0.2±6.3 bpm，P <.01）的24小时心率治疗变化在利拉鲁肽组中。总之，利拉鲁肽治疗不能降低血压。但是，观察到dBP的日变化很小，但不影响BP变异性或夜间BP下降。